Summary
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). ClinicalTrials.gov lists 8 registered trials linking Atezolizumab to Non-Hodgkin Lymphoma (NHL): 1 is currently recruiting; 2 are active or not yet recruiting; 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT02693535). It plans or enrolled 4200 participants. Registration activity spans 2015 to 2021. The literature layer holds 3 publications for this pair: 3 clinical trial publications. Publication years run from 2020 to 2025. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Non-Hodgkin Lymphoma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 48.0 (trials 22.0, literature 6.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 2 active / not yet recruiting, 3 completed, 2 other |
| Linked publications | 3 (3 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | ARID1A |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy 2021 | active, not recruiting | Phase 2 | 15 |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma 2020 | active, not recruiting | Phase 2 | 27 |
| NCT02693535 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer 2016 | recruiting | Phase 2 | 4,200 |
| NCT02594384 | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma 2015 | completed | Phase 1 | 62 |
| NCT04045028 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma 2019 | terminated | Phase 1 | 41 |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma 2019 | terminated | Phase 1 | 4 |
| NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) 2015 | completed | PHASE1, PHASE2 | 713 |
| NCT02596971 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) 2015 | completed | PHASE1, PHASE2 | 91 |
Published literature
- Clinical trial publication Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA groupHerbaux C, Bachy E, Bouabdallah R et al. · British journal of haematology · 2025 · PMID 40285420
- Clinical trial publication Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaOthman T, Frankel P, Allen P et al. · Haematologica · 2025 · PMID 39021209
- Clinical trial publication Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyGeoerger B, Zwaan CM, Marshall LV et al. · The Lancet. Oncology · 2020 · PMID 31780255
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Atezolizumab approved for Non-Hodgkin Lymphoma (NHL)?
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Atezolizumab in clinical trials for Non-Hodgkin Lymphoma (NHL)?
ClinicalTrials.gov lists 8 registered trials linking Atezolizumab to Non-Hodgkin Lymphoma (NHL): 1 is currently recruiting; 2 are active or not yet recruiting; 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT02693535). It plans or enrolled 4200 participants. Registration activity spans 2015 to 2021.
What does the evidence show for Atezolizumab in Non-Hodgkin Lymphoma (NHL)?
Atezolizumab has 3 completed trials and 3 linked publications for Non-Hodgkin Lymphoma (NHL). Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.